N-desalkylquetiapine

A metabolite of the antipsychotic drug quetiapine with distinct pharmacological properties.

N-desalkylquetiapine, also known as norquetiapine, is a pharmacologically active metabolite of the atypical antipsychotic drug quetiapine. It is formed in the body through the metabolism of quetiapine, primarily by the action of the cytochrome P450 enzyme CYP3A4.

Pharmacology

N-desalkylquetiapine exhibits a distinct pharmacological profile compared to its parent compound, quetiapine. While quetiapine is primarily known for its antagonistic effects on dopamine D2 and serotonin 5-HT2A receptors, N-desalkylquetiapine has a higher affinity for the norepinephrine transporter (NET) and acts as a potent norepinephrine reuptake inhibitor (NRI). This action contributes to its antidepressant effects, which are thought to play a role in the therapeutic efficacy of quetiapine in treating major depressive disorder and bipolar disorder.

Receptor Binding

N-desalkylquetiapine binds to several neurotransmitter receptors, including:

• Norepinephrine transporter (NET): Acts as an inhibitor, increasing norepinephrine levels in the synaptic cleft.
• Serotonin 5-HT2C receptor: Acts as an antagonist, which may contribute to its antidepressant effects.
• Histamine H1 receptor: Acts as an antagonist, which may contribute to sedative effects.
• Muscarinic acetylcholine receptors: Acts as an antagonist, which may contribute to anticholinergic side effects.

Clinical Significance

The presence of N-desalkylquetiapine in the body is significant for several reasons:

• Antidepressant Effects: The NRI activity of N-desalkylquetiapine is believed to enhance the antidepressant effects of quetiapine, making it effective in treating depressive episodes in bipolar disorder and major depressive disorder.
• Side Effects: The pharmacological actions of N-desalkylquetiapine can contribute to both therapeutic effects and side effects, such as sedation and anticholinergic effects.

Metabolism

Quetiapine is metabolized in the liver by the cytochrome P450 enzyme system, with CYP3A4 being the primary enzyme responsible for the formation of N-desalkylquetiapine. This metabolic pathway can be influenced by various factors, including drug interactions and genetic polymorphisms affecting CYP3A4 activity.

Research and Development

Research into N-desalkylquetiapine continues to explore its potential as a standalone therapeutic agent, given its distinct pharmacological properties. Studies are investigating its role in mood disorders and its potential benefits and risks when used in combination with other psychotropic medications.

Also see

• Quetiapine
• Atypical antipsychotics
• Norepinephrine reuptake inhibitor
• Cytochrome P450
• Major depressive disorder
• Bipolar disorder